Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Sanne Y. Smith-Apeldoorn"'
Autor:
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Henricus G. Ruhé, Marije aan het Rot, Jeanine Kamphuis, Marrit K. de Boer, Robert A. Schoevers
Publikováno v:
BJPsych Open, Vol 8 (2022)
Background Intravenous infusion of ketamine can produce rapid and large symptom reduction in patients with treatment-resistant depression (TRD) but presents major obstacles to clinical applicability, especially in community settings. Oral esketamine
Externí odkaz:
https://doaj.org/article/7368b2f76c9c4de29a4e976f861824ea
Autor:
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jeanine Kamphuis, Antoinette D. I. van Asselt, Daan J. Touw, Marije aan het Rot, Robert A. Schoevers
Publikováno v:
BMC Psychiatry, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have bee
Externí odkaz:
https://doaj.org/article/315dd20cf3024abb847b34cf87093f1f
Autor:
Jolien K. E. Veraart, Sanne Y. Smith-Apeldoorn, Hayley Trueman, Marrit K. de Boer, Robert A. Schoevers, Rupert McShane
Publikováno v:
BJPsych Open, Vol 4, Pp 389-392 (2018)
BackgroundOff-label ketamine treatment has shown acute antidepressant effects that offer hope for patients with therapy-resistant depression. However, its potential for integration into treatment algorithms is controversial, not least because the evi
Externí odkaz:
https://doaj.org/article/eda330df8ec84b12bb5488cb30a1d277
Autor:
Sanne Y Smith-Apeldoorn, Maurice Vischjager, Jolien KE Veraart, Jeanine Kamphuis, Marije aan het Rot, Robert A Schoevers
Publikováno v:
Journal of Psychopharmacology. 36(5):531-544
Background: The introduction of esketamine into the field of psychiatry comes on the heels of excitement from studies on racemic ketamine. While the intranasal route has been the most studied to date, other modes of administration of esketamine may a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e7c30c45575c89d0e08459fea7531d
https://doi.org/10.1177/02698811221084055
https://doi.org/10.1177/02698811221084055
Autor:
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jeanine Kamphuis, Antoinette D. I. van Asselt, Daan J. Touw, Marije aan het Rot, Robert A. Schoevers
Publikováno v:
BMC Psychiatry, Vol 20, Iss 1, Pp 1-1 (2020)
After publication of our article [1] we were notified that Figure 1 was wrongly presented.
Externí odkaz:
https://doaj.org/article/b735456f1a584e55a8c3bac620855fc3
Autor:
Wim van den Brink, Robert A. Schoevers, Jolien K E Veraart, Sanne Y Smith-Apeldoorn, J J Breeksema, Nina Schimmel
Publikováno v:
Psychopharmacology. 239:15-33
Background: Terminally ill patients may experience existential distress, depression, or anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or pharmacological interventions have (time) limited efficacy. Psychedelic treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7556ce3f23156c0c7be89b81a3a31361
https://doi.org/10.1007/s00213-021-06027-y
https://doi.org/10.1007/s00213-021-06027-y
Autor:
Jolien K. E. Veraart, Sanne Y. Smith-Apeldoorn, Mats Kutscher, Maurice Vischjager, Annemarie van der Meij, Jeanine Kamphuis, Robert A. Schoevers
Publikováno v:
The Journal of clinical psychiatry. 83(6)
Objective: Ketamine is increasingly prescribed for treatment-resistant depression (TRD), often as add-on to regular antidepressants. Augmentation of ketamine to monoamine oxidase inhibitors (MAOIs) is advised against, as this practice might increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9edd88160463f1de143d963f6c1aa7b9
https://doi.org/10.4088/jcp.21m14267
https://doi.org/10.4088/jcp.21m14267
Autor:
Daan J Touw, Berber A E Visser, Robert A. Schoevers, Sanne Y Smith-Apeldoorn, Jeanine Kamphuis, Iris M Bakker, Jolien K E Veraart
Publikováno v:
International Journal of Neuropsychopharmacology
BackgroundThe use of ketamine for depression has increased rapidly in the past decades. Ketamine is often prescribed as an add-on to other drugs used in psychiatric patients, but clear information on drug-drug interactions is lacking. With this revie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80112a26fb94f4007e3606669c8943a0
https://doi.org/10.1093/ijnp/pyab039
https://doi.org/10.1093/ijnp/pyab039
Autor:
Sanne Y Smith-Apeldoorn, Jolien KE Veraart, Jan Spijker, Jeanine Kamphuis, Robert A Schoevers
Publikováno v:
The Lancet Psychiatry, 9, 907-921
The Lancet Psychiatry, 9, 11, pp. 907-921
The Lancet Psychiatry, 9, 11, pp. 907-921
Item does not contain fulltext Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21172257fa0107b58a84dd611d16b801
https://pubmed.ncbi.nlm.nih.gov/36244360
https://pubmed.ncbi.nlm.nih.gov/36244360
Autor:
Jeanine Kamphuis, Robert A. Schoevers, Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Harm-Pieter Spaans
Publikováno v:
Journal of Affective Disorders. 281:82-89
Objective Ketamine has repeatedly shown to have rapid and robust antidepressant effects in patients with treatment resistant depression (TRD). An important question is whether ketamine is as effective and safe as the current gold standard electroconv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da7608758175cfbe44554053fa6d151
https://doi.org/10.1016/j.jad.2020.11.123
https://doi.org/10.1016/j.jad.2020.11.123